Article
Cardiac & Cardiovascular Systems
Jean-Baptiste Guichard, Feng Xiong, Xiao-Yan Qi, Nathalie L'Heureux, Roddy Hiram, Jiening Xiao, Patrice Naud, Jean-Claude Tardif, Antoine Da Costa, Stanley Nattel
Summary: This study assessed the specific contributions of atrial fibrillation-related atrial arrhythmia vs. associated ventricular arrhythmia to remodeling. The results showed that both atrial tachyarrhythmia and rapid ventricular response during AF produce distinct atrial remodelling, providing new insights into AF-related remodeling and ventricular rate-control considerations.
CARDIOVASCULAR RESEARCH
(2021)
Article
Endocrinology & Metabolism
Kosuke Inoue, Rong Guo, Martin L. Lee, Ramin Ebrahimi, Natalia Neverova, Jesse W. Currier, Muhammad T. Bashir, Angela M. Leung
Summary: A retrospective cohort study of U.S. veterans revealed that iodine-induced hyperthyroidism is associated with an increased risk of incident atrial fibrillation/flutter, particularly among females. Further research with a more diverse sample is needed to confirm these sex-based differences and evaluate the cost-benefit analysis of long-term monitoring for cardiac arrhythmias following iodine-induced hyperthyroidism.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Cardiac & Cardiovascular Systems
Jonathan M. Kalman, Ahmed M. Al-Kaisey, Ramanathan Parameswaran, Joshua Hawson, Robert D. Anderson, Michael Lim, David Chieng, Stephen A. Joseph, Alex McLellan, Joseph B. Morton, Paul B. Sparks, Geoffrey Lee, Prashanthan Sanders, Peter M. Kistler
Summary: This study aimed to determine if the timing of catheter ablation for atrial fibrillation (AF) affects arrhythmia outcomes. The results showed that there was no significant difference in the atrial arrhythmia free survival at 12 months post-ablation between patients who underwent early ablation and those who underwent delayed ablation. Other secondary outcomes also showed no significant difference. Therefore, delaying AF ablation by 12 months for antiarrhythmic drug management does not reduce the efficacy of ablation.
EUROPEAN HEART JOURNAL
(2023)
Article
Medicine, General & Internal
Amalia Ioanna Moula, Iris Parrini, Cecilia Tetta, Fabiana Luca, Gianmarco Parise, Carmelo Massimiliano Rao, Emanuela Mauro, Orlando Parise, Francesco Matteucci, Michele Massimo Gulizia, Mark La Meir, Sandro Gelsomino
Summary: Atrial fibrillation (AF) is the most common arrhythmia, with its incidence increasing with age and comorbidities. Obstructive sleep apnea (OSA) is a chronic sleep disorder more commonly found in older men. Previous studies have shown a link between OSA and AF, although the prevalence of OSA in AF patients remains unknown due to underdiagnosis. This meta-analysis investigated the association between OSA and AF, using data from 54,271 patients. A strong link was found between these two disorders, with the incidence of AF being 88% higher in patients with OSA. Age and hypertension were found to independently strengthen this association, indicating that treating OSA may help reduce AF recurrence. Further research is needed to confirm these findings.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Baptiste Maille, Nathalie Lalevee, Marion Marlinge, Juliette Vahdat, Giovanna Mottola, Clara Degioanni, Lucille De Maria, Victor Klein, Franck Thuny, Frederic Franceschi, Jean-Claude Deharo, Regis Guieu, Julien Fromonot
Summary: This narrative review discusses the potential role of the adenosinergic system in the pathophysiology of atrial fibrillation (AF). It provides insights into adenosinergic system signaling and its interactions with AF. Activation of adenosine receptors can affect the occurrence and maintenance of AF, and the adenosinergic system is also associated with the modulation of the autonomic nervous system and AF risk factors.
Letter
Medicine, General & Internal
Isaac W. Leon-acuna, Takeki Suzuki
Summary: Andrade et al. found that initial catheter cryoballoon ablation strategy resulted in lower incidence of persistent atrial fibrillation and lower arrhythmia burden compared to antiarrhythmic drug therapy in patients with paroxysmal atrial fibrillation during 3 years of follow-up. The study builds upon the findings of the EARLY-AF trial and the STOP AF First trial. Due to the relatively small sample size (303 patients) and short follow-up period, it may be difficult to detect mortality benefits of cryoballoon ablation.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Cardiac & Cardiovascular Systems
Zhengjie Wang, Qi Tong, Tao Li, Yongjun Qian
Summary: Atrial fibrillation is a common cardiac arrhythmia that significantly impacts patients' quality of life and leads to various complications. Traditional drug therapy and ablation have limitations, while the use of nano drug delivery system offers a safer, more effective, and cost-effective treatment strategy.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Cardiac & Cardiovascular Systems
Jorge G. Quintanilla, Shlomo Shpun, Jose Jalife, David Filgueiras-Rama
Summary: Modern cardiac electrophysiology has made significant advancements in understanding the mechanisms of atrial fibrillation (AF) and the debate between randomly propagating wavelets and deterministic rotors continues. Recent research supports the feasibility of targeting and ablating AF driver regions outside of pulmonary veins. New technologies and methodologies have provided platforms for clinicians to implement novel approaches in AF ablation procedures.
CARDIOVASCULAR RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Funsho E. Fakuade, Vanessa Steckmeister, Fitzwilliam Seibertz, Judith Gronwald, Stefanie Kestel, Julia Menzel, Julius Ryan D. Pronto, Karim Taha, Fereshteh Haghighi, George Kensah, Charles M. Pearman, Felix Wiedmann, Arco J. Teske, Constanze Schmidt, Katharine M. Dibb, Aschraf El-Essawi, Bernhard C. Danner, Hassina Baraki, Blanche Schwappach, Ingo Kutschka, Fleur E. Mason, Niels Voigt
Summary: This study investigates the role of impaired atrial contractility and arrhythmogenic substrate in the development of postoperative atrial fibrillation (poAF).
CARDIOVASCULAR RESEARCH
(2021)
Review
Cardiac & Cardiovascular Systems
Ludhmila Abrahao Hajjar, Silvia Moulin Ribeiro Fonseca, Theuran Inahja Vicente Machado
Summary: Cancer patients have a higher risk of atrial fibrillation and related thromboembolic and bleeding risks, requiring special management and preventive measures, with challenges in predicting these risks.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Till Freudenberger, Beate Kranz, Waldemar Lehmann, Katja Schaefer, Klaus Muenter, Kichang Lee, Patrick T. Ellinor, William J. Hucker
Summary: The study evaluated 5 canine atrial fibrillation models and found that intermittent long-term atrial tachypacing and local carbachol injection combined with short-term atrial tachypacing were successful in inducing atrial fibrillation, showing potential for future drug development efforts in AF treatment.
Article
Medicine, Research & Experimental
Veronica Jimenez-Sabado, Sergi Casabella-Ramon, Anna Llach, Ignasi Gich, Sandra Casellas, Francisco Ciruela, S. R. Wayne Chen, Jose M. Guerra, Antonino Ginel, Raul Benitez, Juan Cinca, Carmen Tarifa, Leif Hove-Madsen
Summary: This study aimed to examine the impact of I3-blocker treatment on spontaneous calcium release events or transient inward currents (ITI) in patients with atrial fibrillation (AF). The results showed that I3-blocker treatment did not affect calcium current density, but it reduced ITI frequency and calcium spark frequency, as well as the levels of phosphorylated RyR2 and phospholamban.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Michael Murninkas, Roni Gillis, Sigal Elyagon, Or Levi, Wesam Mulla, Amos Katz, Yoram Etzion, Gideon Gradwohl
Summary: This study developed an algorithm to clean atrial signals from ventricular mixing and objectively quantify AF substrate based on waveform complexity. The algorithm efficiently detected irregularity and atrial remodeling, facilitating standardized AF research in rodents.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Derek S. Chew, Yanhong Li, Patricia A. Cowper, Kevin J. Anstrom, Jonathan P. Piccini, Jeanne E. Poole, Melanie R. Daniels, Kristi H. Monahan, Linda Davidson-Ray, Tristram D. Bahnson, Hussein R. Al-Khalidi, Kerry L. Lee, Douglas L. Packer, Daniel B. Mark
Summary: In the CABANA trial, catheter ablation was found to be economically attractive compared with drug therapy for treating atrial fibrillation, based on projected incremental quality-adjusted life years (QALYs) but not life years (LYs) alone.
Article
Cardiac & Cardiovascular Systems
Ulrich Schotten, Seungyup Lee, Stef Zeemering, Albert L. Waldo
Summary: Determining the sequence of activation in atrial fibrillation (AF) is vital for understanding its electrophysiological mechanism(s), but the complex nature of electrograms has posed challenges. Different approaches have led to varied interpretations of AF mechanisms, with a lack of a comprehensive consensus. Traditional views propose multiple wavelets, various types of re-entry, but a universally accepted paradigm for AF mechanisms is still missing.
Article
Multidisciplinary Sciences
David Tinaquero, Teresa Crespo-Garcia, Raquel G. Utrilla, Paloma Nieto-Marin, Andres Gonzalez-Guerra, Marcos Rubio-Alarcon, Anabel Camara-Checa, Maria Dago, Marcos Matamoros, Marta Perez-Hernandez, Maria Tamargo, Jorge Cebrian, Jose Jalife, Juan Tamargo, Juan Antonio Bernal, Ricardo Caballero, Eva Delpon
SCIENTIFIC REPORTS
(2020)
Review
Cardiac & Cardiovascular Systems
Seif El Hadidi, Giuseppe Rosano, Juan Tamargo, Stefan Agewall, Heinz Drexel, Juan Carlos Kaski, Alexander Niessner, Basil S. Lewis, Andrew J. S. Coats, Gianluigi Savarese
Summary: Heart failure is a chronic and potentially life-threatening condition. To improve clinical outcomes and avoid inappropriate drug prescriptions, a comprehensive prescribing review tool is compiled based on the latest guidelines, scientific evidence, and expert opinions.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Review
Cardiac & Cardiovascular Systems
Emma Forton Magavern, Juan Carlos Kaski, Richard M. Turner, Heinz Drexel, Azara Janmohamed, Andrew Scourfield, Daniel Burrage, Christopher N. Floyd, Elizabeth Adeyeye, Juan Tamargo, Basil S. Lewis, Keld Per Kjeldsen, Alexander Niessner, Sven Wassmann, Patrick Sulzgruber, Pascal Borry, Stefan Agewall, Anne Grete Semb, Gianluigi Savarese, Munir Pirmohamed, Mark J. Caulfield
Summary: There is a growing body of evidence supporting the use of pharmacogenomics in cardiovascular pharmacology, but international cardiovascular societies lack a common position on the diverse availability, interpretation, and application of such data, as well as the challenges presented by variations in clinical practice across European countries. In addition to barriers to implementing pharmacogenomic testing and complexity in acting on results, there are disparities in the availability of resources and expertise internationally within Europe. Legal and ethical considerations for genomic testing and clinical therapeutic application also require serious thought.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Editorial Material
Cardiac & Cardiovascular Systems
Jose Luis Merino, Juan Tamargo
CARDIOVASCULAR DRUGS AND THERAPY
(2021)
Editorial Material
Cardiac & Cardiovascular Systems
Juan Tamargo, Stefan Agewall
Summary: This study investigates the association between oral fluoroquinolones and the risk of aortic or mitral regurgitation, suggesting a potential link between these drugs and valvular heart disease.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Marta Alonso-Fernandez-Gatta, Maria Gallego-Delgado, Ricardo Caballero, Eduardo Villacorta, Elena Diaz-Pelaez, Belen Garcia-Berroca, Teresa Crespo-Garcia, Beatriz Plata-Izquierdo, Elena Marcos-Vadillo, Luisa Garcia-Cuenllas, Manuel Barreiro-Perez, Maria Isidoro-Garcia, Juan Tamargo-Menendez, Eva Delpon, Pedro L. Sanchez
Summary: The combined phenotype of SSS, LAD, and LVNC is associated with the heritable HCN4 c.1123C >T;(p.R375C) variant. All affected patients in the family carried the HCN4 c.1123C >T;(p.R375C) variant, while unaffected individuals did not. The amplitude and densities of the HCN4 currents generated by the mutant p.R375C HCN4 channels were significantly lower than those generated by wild-type channels.
REVISTA ESPANOLA DE CARDIOLOGIA
(2021)
Article
Cardiac & Cardiovascular Systems
Jose Lopez-Sendon, Raul Moreno, Juan Tamargo
Summary: The treatment of ischemic heart disease involves three pillars: a healthy lifestyle, myocardial revascularisation, and medical therapy. The ISCHEMIA trial compared an early invasive strategy with revascularisation plus optimal medical therapy against initial optimal medical therapy alone with revascularisation reserved for inadequate symptom control. The study included over 5,000 patients with stable coronary artery disease and moderate to severe myocardial ischemia, and found no significant differences in relevant clinical outcomes over a follow-up of 3.2 years.
EUROPEAN CARDIOLOGY REVIEW
(2021)
Review
Cardiac & Cardiovascular Systems
Juan Tamargo, Jose Lopez-Sendon
Summary: The advances in the diagnosis and treatment of coronary artery diseases have greatly reduced mortality rates and extended life expectancy. It is important for patients to adopt a healthy lifestyle, control risk factors, and take medications to prevent heart attacks. Tailored therapy for angina, the most common symptom of chronic coronary artery disease, involves selecting antianginal drugs based on the individual patient's profile.
Editorial Material
Cardiac & Cardiovascular Systems
Juan Tamargo, Koji Hasegawa, Stefan Agewall
EUROPEAN HEART JOURNAL
(2022)
Review
Cardiac & Cardiovascular Systems
Juan Tamargo, Juan Carlos Kaski, Takeshi Kimura, Jack Charles Barton, Ko Yamamoto, Maki Komiyama, Heinz Drexel, Basil S. Lewis, Stefan Agewall, Koji Hasegawa
Summary: Awareness of racial/ethnic disparities in cardiovascular disease is crucial for providing effective healthcare. Differences in prevalence, risk factors, and drug response among different ethnic groups are mainly related to genetic variations. Understanding these differences helps optimize treatment and improve outcomes.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2022)
Article
Physiology
Teresa Crespo-Garcia, Marcos Rubio-Alarcon, Anabel Camara-Checa, Maria Dago, Josu Rapun, Paloma Nieto-Marin, Maria Marin, Jorge Cebrian, Juan Tamargo, Eva Delpon, Ricardo Caballero
Summary: The p.S1054Y SUR2A mutation associated with Cantu syndrome increases the open probability and conductance of ATP-sensitive potassium channels, disrupts the interaction between ankyrin B and K-ATP channels, and reduces the membrane expression of channel subunits, possibly explaining the mild phenotype associated with this mutation.
JOURNAL OF GENERAL PHYSIOLOGY
(2022)
Article
Cell Biology
Maria Dago, Teresa Crespo-Garcia, Anabel Camara-Checa, Josu Rapun, Marcos Rubio-Alarcon, Maria Marin, Juan Tamargo, Ricardo Caballero, Eva Delpon
Summary: Dapagliflozin (dapa) and empagliflozin (empa) are drugs that can increase sodium and potassium ion currents in cardiomyocytes, making them a potential new class of antiarrhythmic drugs.
Review
Cardiac & Cardiovascular Systems
Juan Tamargo, Stefan Agewall, Claudio Borghi, Claudio Ceconi, Elisabetta Cerbai, Gheorghe A. Dan, Peter Ferdinandy, Erik Lerkevang Grove, Bianca Rocca, Patrick Sulzgruber, Anne Grete Semb, Samuel Sossalla, Alexander Niessner, Juan Carlos Kaski, Dobromir Dobrev
Summary: Cardiovascular diseases (CVD) are the leading cause of death globally, and current pharmacotherapy is not optimal. Therefore, there is an urgent need to develop new drugs with higher efficacy and better safety profiles. This review summarizes the recent advances in cardiovascular pharmacology in 2022, including the approval of first-in-class drugs for the treatment of obstructive hypertrophic cardiomyopathy, type 2 diabetes mellitus, and heart failure independent of left ventricular ejection fraction. It also discusses the repurposing of existing drugs and the potential of new therapies for the treatment of various cardiovascular diseases.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Paloma Nieto-Marin, Juan Jimenez-Jaimez, David Tinaquero, Silvia Alfayate, Raquel G. Utrilla, Maria del Mar Rodriguez Vazquez del Rey, Francesca Perin, Georgia Sarquella-Brugada, Lorenzo Monserrat, Josep Brugada, Luis Tercedor, Juan Tamargo, Eva Delpon, Ricardo Caballero
REVISTA ESPANOLA DE CARDIOLOGIA
(2019)
